Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1F | P30939 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPR1 | P16066 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566036 | 0.85 | LMNA (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGLMNA | |
| SCHEMBL1338153 | 0.82 | LMNA (0.37) | PIK3CDPIK3CAPIK3CBPIK3CGLMNA | |
| SCHEMBL565648 | 0.82 | LMNA (0.37) | PIK3CDPIK3CAPIK3CBPIK3CGLMNA | |
| SCHEMBL565814 | 0.79 | SMN1; SMN2 (0.38) | PIK3CDPIK3CAPIK3CBPIK3CGLMNA | |
| SCHEMBL2676180 | 0.77 | DPP4 (0.46) | HTR2C | |
| SCHEMBL2676359 | 0.75 | HTR2C (0.44) | HTR2C | |
| SCHEMBL31392972 | 0.71 | MAPT (0.41) | MAPTHTTHTR1AHTR1DHTR1F | |
| SCHEMBL27266065 | 0.70 | SCN9A (0.35) | PIK3CDHTR1AHTR1DHTR1FHTR2A | |
| SCHEMBL31165549 | 0.69 | PARP1 (0.43) | LMNABLMMAPTHTTTP53 | |
| SCHEMBL3153823 | 0.69 | NPY5R (0.36) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346505-B1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2346505-B1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8697689-B2 | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-04-15 | — | — | US | disclosed |
| US-8691813-B2 | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691813-B2 | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2373649-B1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2373649-B1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | disclosed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | disclosed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | disclosed |
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. | 2011-11-10 | — | — | US | disclosed |
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. | 2011-11-10 | — | — | US | disclosed |
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. | 2011-11-10 | — | — | US | disclosed |
| EP-2373649-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2346505-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010060589-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010060589-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010043396-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043396-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM1, GRM5 | PIK3CD 1731/4885PIK3CA 2746/4885PIK3CB 2169/4885 |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM5, GRIA2 | PIK3CD 1584/4885PIK3CA 2527/4885PIK3CB 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.